Pemetrexed(500mg/m2) and bevacizumab(15mg/kg) will be administered triweekly until disease progression.

2 trials

Sponsors

Department of Respiratory Medicine and Rheumatology, Institute of Health Biosciences, The University of Tokushima Graduate School, Yamaguchi Thoracic Oncology Group (YTOG)

Conditions

elderly patients with stage IIIB/IV non-small cell lung cancer except for squamous cell carcinoma

Phase 2

A phase II trial of pemetrexed/bevacizumab in the first-line treatment of elderly patients with advanced non-small cell lung cancer.

Active, not recruitingJPRN-UMIN000008764

Department of Respiratory Medicine and Rheumatology, Institute of Health Biosciences, The University of Tokushima Graduate Schoolelderly patients with stage IIIB/IV non-small cell lung cancer except for squamous cell carcinoma

Start: 2012-10-01Target: 36Updated: 2026-06-29

A phase II study of Pemetrexed combination with Bevacizumab in the first-line treatment of elderly patients with advanced Non-squamous Non-small cell lung cancer

RecruitingJPRN-UMIN000009129

Yamaguchi Thoracic Oncology Group (YTOG)elderly patients with stage IIIB/IV non-small cell lung cancer except for squamous cell carcinoma

Start: 2012-10-01Target: 40Updated: 2026-06-29